Targeting PD-L1 Glycosylation with Site-Specific Aptamers for Enhanced Immune Checkpoint Blockade
Nano Letters · 19.08.2026 · 26 (32) · 10617-10626
DOI: 10.1021/acs.nanolett.6c01322 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nano Letters, online erschienen am 03.08.2026. Verfasst von Wenfei Guo und 11 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Science and Biomedicine Laboratory (MBL), State Key Laboratory of Chemo and Biosensing, College of Chemistry and Chemical Engineering, Coll…. Hauptthemen laut MEDLINE: B7-H1 Antigen, Aptamers, Nucleotide, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Ministry of Education of the People's Republic of China, National Key Research and Development Program of China.
Abstract (Originalsprache)
Programmed death-ligand 1 (PD-L1) critically relies on extensive N-glycosylation at four conserved sites to regulate its immune-checkpoint function. However, the distinct roles of individual glycans remain poorly understood because of a lack of site-specific tools, which also limits the efficacy of current PD-1/PD-L1 blockade therapies. Here, we developed a glycoprotein-targeted Systematic Evolution of Ligands by EXponential enrichment platform (Glyco-SELEX) using an indole-incorporated DNA library to screen aptamers against epitope-specific glycans. Using natively glycosylated PD-L1 isolated from cell membranes as the selection target, we identified a panel of aptamers that can discriminate glycosylation sites on PD-L1. Our results demonstrated that aptamers targeting glycans at the N35 or N192 site effectively disrupt the PD-1/PD-L1 interaction. Moreover, by engineering a bivalent aptamer directed against both sites, the antitumor activity of CAR-T cells was significantly enhanced. This work not only resolves the functional ambiguity of PD-L1 glycosylation but also establishes a versatile platform for developing therapeutics against epitope-specific glycans.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Molecular Science and Biomedicine Laboratory (MBL), State Key Laboratory of Chemo and Biosensing, College of Chemistry and Chemical Engineering, College of Biology, Aptamer Engineering Center of Hunan Province, Hunan Un…
- Department of Clinical Laboratory, Zhejiang Cancer Hospital, Zhejiang Key Laboratory of Functional Nucleic Acids for Basic and Clinical Application, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Han…
- Medical School, University of Chinese Academy of Sciences, Beijing101408, China.
ORCID-Profile: Tao Bing, Yajun Wang, Liping Qiu, Weihong Tan
Förderung
- National Natural Science Foundation of China
- Ministry of Education of the People's Republic of China
- National Key Research and Development Program of China
- Science and Technology Program of Hunan Province
- Leading Innovative and Entrepreneur Team Introduction Program of Zhejiang Province
Zitieren
APA
Guo, W., Yang, W., Zhu, X., Wang, Z., Zhang, C., He, Y., Wu, H., Bing, T., Wang, Y., Wang, Z., Qiu, L., & Tan, W. (2026). Targeting PD-L1 Glycosylation with Site-Specific Aptamers for Enhanced Immune Checkpoint Blockade. Nano Letters, 26(32), 10617-10626. https://doi.org/10.1021/acs.nanolett.6c01322
Vancouver
Guo W, Yang W, Zhu X, Wang Z, Zhang C, He Y, et al. Targeting PD-L1 Glycosylation with Site-Specific Aptamers for Enhanced Immune Checkpoint Blockade. Nano Letters. 2026;26(32):10617-10626. doi:10.1021/acs.nanolett.6c01322
BibTeX
@article{Guo2026,
author = {Guo, Wenfei and Yang, Weihong and Zhu, Xiuxiu and Wang, Zhaoyang and Zhang, Chengjing and He, Yao and Wu, Hui and Bing, Tao and Wang, Yajun and Wang, Zhimin and Qiu, Liping and Tan, Weihong},
title = {Targeting PD-L1 Glycosylation with Site-Specific Aptamers for Enhanced Immune Checkpoint Blockade},
journal = {Nano Letters},
year = {2026},
volume = {26},
number = {32},
pages = {10617--10626},
doi = {10.1021/acs.nanolett.6c01322}
}
EUVIMED